24.80Open24.80Pre Close0 Volume26 Open Interest230.00Strike Price0.00Turnover43.06%IV0.68%PremiumDec 20, 2024Expiry Date23.07Intrinsic Value100Multiplier20DDays to Expiry1.73Extrinsic Value100Contract SizeAmericanOptions Type0.8482Delta0.0093Gamma9.85Leverage Ratio-0.1737Theta0.1021Rho8.35Eff Leverage0.1382Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet